A Dose Ranging Trial of GSK1349572 and 2 NRTI in HIV-1 Infected, Therapy Naive Subjects
Status:
Completed
Trial end date:
2016-12-22
Target enrollment:
Participant gender:
Summary
This Phase IIb study in HIV-infected antiretroviral naive subjects will select an optimal
once daily dose of GSK1349572 from a range of doses for future evaluation.